Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J. Tettero JM, et al. Among authors: maertens j. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. eCollection 2022. Front Oncol. 2022. PMID: 36300090 Free PMC article.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Tettero JM, et al. Among authors: maertens j. Haematologica. 2023 Oct 1;108(10):2794-2798. doi: 10.3324/haematol.2022.282639. Haematologica. 2023. PMID: 37021540 Free PMC article. No abstract available.
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis JH, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen JJ, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M. Giebel S, et al. Among authors: maertens j. Am J Hematol. 2023 Apr;98(4):580-587. doi: 10.1002/ajh.26825. Epub 2023 Jan 10. Am J Hematol. 2023. PMID: 36626592 Free article.
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis.
Servais S, Baron F, Lechanteur C, Seidel L, Baudoux E, Briquet A, Selleslag D, Maertens J, Poire X, Schroyens W, Graux C, De Becker A, Zachee P, Ory A, Herman J, Kerre T, Beguin Y. Servais S, et al. Among authors: maertens j. Front Immunol. 2023 Feb 1;14:1106464. doi: 10.3389/fimmu.2023.1106464. eCollection 2023. Front Immunol. 2023. PMID: 36817464 Free PMC article.
Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.
Devillier R, Eikema DJ, Dufour C, Aljurf M, Wu D, Maschan A, Kulagin A, Halkes CJM, Collin M, Snowden J, Renard C, Ganser A, Sykora KW, Gibson BE, Maertens J, Itäla-Remes M, Corti P, Cornelissen J, Bornhäuser M, Araujo MC, Ozdogu H, Risitano A, Socie G, De Latour RP. Devillier R, et al. Among authors: maertens j. Haematologica. 2023 Sep 1;108(9):2305-2315. doi: 10.3324/haematol.2022.281876. Haematologica. 2023. PMID: 36951165 Free PMC article.
On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Guisnel C, Schirmer L, Morisset S, Robin M, Labussière-Wallet H, Dulery R, Ceballos P, Forcade E, Nguyen-Quoc S, Poire X, Maertens J, Chantepie S, Chevallier P, Daguindau E, Villate A, Charbonnier A, Castilla-Llorente C, Contentin N, Huynh A, Yakoub-Agha I, Bulabois CE, Rubio MT, D'Aveni M. Guisnel C, et al. Among authors: maertens j. Acta Haematol. 2023;146(3):230-239. doi: 10.1159/000528184. Epub 2023 Jan 5. Acta Haematol. 2023. PMID: 36603565
Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Scheid C, Eikema DJ, Van Gelder M, Salmenniemi U, Maertens J MD, Passweg JR, Blaise D, Byrne JL, Kroeger N, Sockel K, Chevallier P, Bourhis JH, Cornelissen JJ, Sengeloev H, Finke J, Snowden JA, Gedde-Dahl T, Cornillon J, Schanz U, Patel A, Koster L, de Wreede LC, Hayden PJ, Raj K, Drozd-Sokolowska J, Gurnari C, Onida F, McLornan DP, Robin M, Yakoub-Agha I. Scheid C, et al. Among authors: maertens j md. Blood. 2024 May 10:blood.2023022273. doi: 10.1182/blood.2023022273. Online ahead of print. Blood. 2024. PMID: 38728380
Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
De Greef J, Averbuch D, Tondeur L, Duréault A, Zuckerman T, Roussel X, Robin C, Xhaard A, Pagliuca S, Beguin Y, Botella-Garcia C, Khanna N, Le Bourgeois A, Van Praet J, Ho A, Kröger N, Ducastelle Leprêtre S, Roos-Weil D, Aljurf M, Blijlevens N, Blau IW, Carlson K, Collin M, Ganser A, Villate A, Lakner J, Martin S, Nagler A, Ram R, Torrent A, Stamouli M, Mikulska M, Gil L, Wendel L, Tridello G, Knelange N, de la Camara R, Lortholary O, Fontanet A, Styczynski J, Maertens J, Coussement J, Lebeaux D. De Greef J, et al. Among authors: maertens j. J Infect. 2024 Apr 23;88(6):106162. doi: 10.1016/j.jinf.2024.106162. Online ahead of print. J Infect. 2024. PMID: 38663756 Free article.
559 results